ClinicalTrials.gg
RecruitingNCT06923878CRDUpdated Apr 9, 2026

Comparison of Skin Prick Testing, Extract-specific IgE Antibody Testing and Component Resolved Diagnosis in Diagnosing of Legume Allergy

An observational study in Food Allergy Suspected, sponsored by University Hospital Pilsen. Recruiting at 1 site in Czechia. Open to participants aged 4 Months to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by University Hospital Pilsen · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
100
Ages
4 Months to 65 Years
Sex
All
01

Study summary

The study is aimed at improving the diagnosis of food allergy, specifically allergy to commonly consumed legumes such as peas, lentils, chickpeas or green beans. Patients suspected of allergy to these legumes will be examined using traditional methods of IgE-mediated allergy diagnosing (skin prick test, testing for specific IgE antibodies against food extract), but also by testing for specific IgE antibodies against relevant allergenic molecules of these legumes. The results of performed tests will be compared with the result of the oral food challenge, which is considered to be the gold standard of food allergy diagnosis.

Read the detailed description

Legumes are one of the major food allergens, but these are usually peanuts or soybeans. Other legumes, such as peas, lentils, chickpeas or green beans, have been overlooked, but some studies suggest that they may also cause allergic reactions ranging from urticaria to anaphylaxis. The prevalence of allergy to these neglected legumes can range widely (0.5-39.6%) depending on the patient group and the method of allergy diagnosis.

The main allergens of legumes are the seed storage proteins, including 7S and 11S globulins and especially 2S albumins, which can cause the most severe, often systemic allergic reactions. These proteins are characterized by their considerable resistance to heat and other physical or chemical influences. Other important legume allergens in our geographical area are the PR-10 proteins cross-reacting with the major allergen of birch pollen (Bet v 1), which in turn are more sensitive to heat treatment and tend to be the source of milder, more local reactions. In contrast, sensitization to other allergen groups, such as lipid transfer proteins (LTPs), oleosins or profilins, is less significant.

02

Conditions studied

  • Food Allergy Suspected

Browse trials for

Keywords

  • food allergy
  • component resolved diagnosis
  • skin prick test
  • oral food challenge
  • legume allergy
03

In context

Food Hypersensitivity

378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.

This study's planned enrollment of 100 is below the median of 149 across 120 observational studies indexed under Food Hypersensitivity.

Browse Food Hypersensitivity studies →

Lead sponsor

University Hospital Pilsen is the lead sponsor of 10 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Months to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

European population, Caucasian race

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age: ≤ 65 years
  • signing to the study
  • a positive history of an immediate allergic reaction to one or more of the legumes studied (peas, lentils, chickpeas, beans) with skin, gastrointestinal, respiratory or cardiovascular symptoms occurring within 2 hours after ingestion and a positive result of specific IgE testing against ALEX and/or skin prick test with the legume
  • patients with a positive OFC with any of the legumes studied

Exclusion criteria

Exclusion Criteria:

  • disagreement with the implementation of the oral food challenge
  • history of severe systemic allergic reaction to the legume in question (Ring-Messmer grade ≥ 3)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1

    Patients with food allergy

  • Group 2

    Healthy volunteers

06

What researchers measure

Primary outcomes

  1. Specificity and sensitivity of the tests performed

    Specificity and sensitivity of the tests performed

    Time frame: 6 months

Secondary outcomes

  1. Food challenge protocol

    Food challenge protocol

    Time frame: From enrollment and no later than one.

  2. Specific lultiplex assay including allergenic component of legumes

    Specific multiplex assay including legume allergenic components

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Oct 2028, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Apr 11, 2025
StartActual
Oct 1, 2023
Primary completionEst.
Oct 1, 2028
CompletionEst.
Mar 31, 2029
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06923878
Lead sponsor
University Hospital Pilsen
Collaborators
MacroArray Diagnostics GmbH
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
Oct 1, 2023
Primary completion
Oct 1, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Apr 9, 2026

Study contacts

Martin Liska, MD
Contact
liska@fnplzen.cz
+420377103390
Martin Liska, MD
principal investigator · Department of allergology and immunology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion